Search results
Results from the WOW.Com Content Network
The Biomedical Advanced Research and Development Authority (BARDA) is a center within the Administration for Strategic Preparedness and Response [1] (ASPR) located within the U.S. Department of Health and Human Services (HHS) responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear ...
"NOVAVAX, a pharmaceutical company in Rockville, Md., announced this week that in preliminary results of two phase 1 clinical trials, its H5N1 avian influenza vaccine candidate was found to be safe and effective. The company conducted the trials under its contract with the US Biomedical Advanced Research and Development Authority (BARDA).
The stop-work order comes as 10,000 individuals were slated to begin clinical trials on Monday. ... BARDA obligated roughly $460 million to Vaxart's development of the new vaccine, with a total of ...
Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering. Nabaparna Bhattacharya. June 14, 2024 at 9:06 AM. ... Click here to start Your 14-Day Trial Now!
In March 2020, the phase I human trial of mRNA-1273 began in partnership with the US National Institute of Allergy and Infectious Diseases. [130] In April, the US Biomedical Advanced Research and Development Authority (BARDA) allocated up to $483 million for Moderna's vaccine development. [131]
This latest financial support comes on top of the $176 million BARDA gave Moderna last summer. ... Another Phase III trial will target H7N9, according to HHS. In order to combat “multiple health ...
The new award follows a $483 million grant provided by BARDA in April, which means Moderna has now received a total of $955 million in funding from the U.S. government.The award coincides with the ...
In December 2020, Novavax started the PREVENT-19 (NCT04611802) phase III trial in the US and Mexico, funded by NIAID and BARDA. [79] [80] In May 2021, Novavax initiated a pediatric expansion for the phase III clinical trial, with 3,000 adolescents 12–17 years of age in up to 75 sites in the United States. [81]